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Abstract 
 
Nowadays, the role of peritoneal dialysis as a renal replacement therapy in end-stage renal 
disease is strongly established. However, over the years peritoneal dialysis has been used for the 
management of clinical situations not directly related to end-stage renal disease, such as congestive 
heart failure, pancreatitis, psoriasis, hypothermia, intraperitoneal chemotherapy and refractory ascites. 
Congestive heart failure is a major cause of mortality and morbidity in the general population. 
The development of diuretic resistance or the establishment of the cardiorenal syndrome may hamper 
the adequate control of fluid retention manifestations. Whether in a scenario of acute decompensation 
of congestive heart failure or in the chronic treatment of refractory congestive heart failure, 
ultrafiltration techniques are proposed.  
Cirrhosis represents a late stage of chronic liver disease and, like heart failure, has a high 
morbidity and mortality associated. Its most frequent complication is ascites that, in a minority of 
patients, can become refractory to the conventional therapy. In this context recurrent paracentesis is 
the more solid option. Once hepatorenal syndrome is established or whether the patient has associated 
chronic kidney and liver disease, renal replacement therapy may be necessary. In that scenario 
hemodialysis can be difficult to perform, since liver dysfunction may result in a tendency to chronic 
hypotension. Peritoneal dialysis can present some advantages over hemodialysis, such as greater 
hemodynamic tolerance due to the slower rate of ultrafiltration performed by this technique. 
This paper aims to review the literature in order to understand the peritoneal dialysis 
applicability in congestive heart failure, chronic liver disease and others. 
 
Key-words: ascites; cardio-renal syndrome; chronic kidney failure; heart failure; hepatorenal syndrome; 
peritoneal dialysis. 
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Resumo 
  
Atualmente, o papel da diálise peritoneal enquanto terapia de substituição renal na doença 
renal crónica terminal encontra-se definitivamente estabelecido. No entanto, ao longo dos anos, a 
diálise peritoneal tem sido utilizada para o tratamento de várias situações clínicas não exclusivamente 
relacionadas com doença renal crónica terminal, tais como a insuficiência cardíaca congestiva, a 
pancreatite, a psoríase, a hipotermia grave, a quimioterapia intraperitoneal e a ascite refratária. 
A insuficiência cardíaca congestiva é uma das principais causas de morbilidade e mortalidade na 
população geral. O desenvolvimento de resistência aos diuréticos ou o estabelecimento da síndrome 
cardiorrenal pode dificultar o controlo da retenção de água e sódio. Quer na descompensação aguda da 
insuficiência cardíaca congestiva, quer no tratamento crónico da insuficiência cardíaca refratária, as 
técnicas de ultrafiltração são propostas como uma opção terapêutica promissora.  
A cirrose representa uma fase tardia da doença hepática crónica e, tal como na insuficiência 
cardíaca, tem uma elevada mortalidade e morbilidade associadas. A sua complicação mais frequente é a 
ascite que, numa minoria de pacientes, pode-se tornar refratária à terapia convencional. Neste 
contexto, a paracentese recorrente é a opção mais sólida. Uma vez estabelecido o síndrome hepato-
renal ou caso o paciente possua doença renal e doença hepática crónica associadas, a terapia de 
substituição renal pode ser necessária. Nesta situação, a hemodiálise pode ser difícil de realizar, dado 
que a disfunção hepática pode resultar na tendência para a hipotensão crónica, dificultando a 
ultrafiltração. A diálise peritoneal pode apresentar, assim, algumas vantagens sobre a hemodiálise, uma 
vez que se associa a uma maior tolerância hemodinâmica relacionada com a capacidade de assegurar 
uma ultrafiltração lenta.  
Este trabalho tem como objetivo rever a literatura no sentido de compreender a aplicação da 
diálise peritoneal na insuficiência cardíaca e na doença renal crónica, entre outras. 
 
Palavras-chave: ascite; diálise peritoneal; insuficiência cardíaca; insuficiência renal crónica; síndrome 
cardio-renal; síndrome hepato-renal.   
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Introduction 
 
Peritoneal Dialysis (PD) is considered mainly a renal replacement therapy (RRT). Since 1976, it 
has been used for the management of patients with end-stage renal disease (ESRD) [1]. Despite the fact 
that equivalent outcomes have been described for both hemodialysis and peritoneal dialysis, some 
potentials advantages can be selectively attributed to PD, such as treatment cost, improved quality of 
life and better  preservation of residual renal function  [2]. PD is a versatile renal replacement technique 
whose particular features open a window of multiple possibilities. Its applicability in non-renal clinical 
conditions has been repeatedly described, and the encouraging results observed reinforce the potential 
of PD to be expanded to other specific medical contexts. 
In the past 80 years, PD has been used for the management of different medical situations that 
are not primarily related to renal disease, such as congestive heart failure (CHF), pancreatitis, psoriasis, 
hypothermia, chronic liver disease (CLD) and intraperitoneal chemotherapy administration [3, 4]. 
CHF is a chronic disease whose incidence is increasing. It is associated with high mortality, 
hospitalization and readmission rates [5, 6]. The typical symptoms of breathless, fatigue or palpitations 
with or without exercise are due to the salt and fluid retention that can be managed with appropriate 
therapy [7]. The development of refractory disease brings the need of new techniques to overcome that 
problem, an area where ultrafiltration techniques such as peritoneal dialysis can take place [8]. Faster 
fluid removal, increased sodium removal, removal of pro-inflammatory cytokines and the possibility to 
restore the response to diuretics are some of the features that turn PD appealing in this context [9, 8]. 
PD can be performed as a daily, continuous, slow ultrafiltration technique in patients with CHF. Being a 
home-based therapy [10], it can have significant impact in the quality of life of these patients.  
 Chronic liver disease (CLD) at some point ends up in cirrhosis. Ascites is the most common 
complication of cirrhosis [11] and its establishment occurs due to portal hypertension and renal sodium 
retention [12]. Treatment of ascites includes the correction of the underlying pathophysiological 
processes of the liver disease [13]. The development of refractory ascites leads, almost inevitably to the 
need of other forms of treatment, such as paracentesis and transjugular intrahepatic portosystemic 
shunt (TIPS) [13]. During the course of the disease some patients evolve to an advanced phase of 
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hemodynamic dysfunction [14].  At this point, a functional form of renal failure named hepatorenal 
syndrome (HRS) takes place [15]. HRS type 2 is related to a progressive deterioration of renal function 
and clinically manifests as refractory ascites [16]. A part of the treatment of HRS involves the 
management of renal failure and at this point RRT can be a viable option [17]. In this setting HD has 
important restrictions, such as unstable hemodynamic status, that can be overcome by PD, thanks to 
the slower rate of ultrafiltration performed by this technique [4].     
This paper aims to review the literature in order to understand the pathogenesis of cardiac 
heart failure and chronic liver disease, as well as the complications that can present as challenges to 
treatment, such as the cardiorenal and the hepatorenal syndromes. The availability and the 
understanding of RRT techniques, especially PD, are explored in order to recognize its applicability as an 
alternative form of therapy for these cases. 
 
 
Methods 
 
  A search through PubMed was performed using the MeSH terms "peritoneal dialysis" or 
"chronic renal disease" or "cardiorenal syndrome" or "congestive heart failure" or "ascites" or 
"hepatorenal syndrome". The combination of the terms "peritoneal dialysis" and "congestive heart 
failure" or "peritoneal dialysis" and "ascites" was also investigated. The articles were selected according 
to the importance for the proposed topic after reading the abstracts, including only articles written in 
english language. Most of the selected articles were published in the last 15 years. Articles with 
relevance to the work obtained from references of selected reviews were also included. Considering the 
inclusion criteria, 68 articles were cited. 
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Chronic kidney disease 
 
 Chronic kidney disease (CKD) presents as a public health problem, with a rising incidence and 
prevalence of kidney failure in the United States, having generally poor outcomes and high cost. 
The Kidney Disease Outcome Quality Iniciative (KDOQI) Clinical Practice Guidelines for Chronic 
Kidney Disease suggested a definition based on two components:  
1) Kidney damage for at least ≥ 3 months, as defined by structural or functional abnormalities 
of the kidney, with or without decreased glomerular filtration rate (GFR); 
2) GFR < 60 mL/min/1.73 m
2
 for ≥ 3 months, with or without kidney damage [18]. 
So, according to this definition, a CKD patient is any person who, regardless of the cause, has a 
GFR of ≤ 60 mL/min/1.73 m
2
 or a GFR of ≥ 60 mL/min/1.73m
2
 plus at least one marker of renal 
parenchymal injury (e.g., proteinuria), present for at least ≥ 3 months [18, 19]. 
 KDOQI has suggested staging CKD into 5 stages (table I). Stage 1 and 2, being the mildest stages, 
with GFR still above 60 ml/min/1.73m
2
, demand evidence for kidney damage. Stage 3, 4 and 5, the more 
severe stages, are presented when GFR is below 60, 30 and 15 mL/min/1.73m
2
, correspondingly [18, 
20].  
Kidney disease appears to result from several physiological adaptations deriving from a 
multiplicity of causes. Glomerular kidney disease, interstitial and tubular disorders, vascular disorders, 
obstructive uropathy, diabetes and hypertension are possible causes of progressive lost of kidney 
function [21, 22]. The decline of GFR frequently results in sodium retention and volume expansion 
leading to elevated blood pressure, metabolic acidosis, disorders of calcium and phosphate metabolism 
with bone disease, cardiovascular disturbances, hematologic abnormalities represented by normocytic, 
normochromic anemia, neuropathy and malnutrition. All the described symptoms and signs constitute 
the uremic syndrome [18, 23, 24]. There are a number of risk factors for the progression of kidney 
disease that can be classified as modifiable, such as hypertension, proteinuria, anemia, dyslipidemia, 
diabetes, smoking and body mass index (BMI), or as non-modifiable, for example, age, gender and 
genetic background [25, 22]. Early diagnosis represents a cornerstone in the management of CKD 
patients, because it allows simultaneously the recognition and modification of several risk factors and 
the implementation of a treatment plan, oriented to slow the rate of disease of progression [21]. 
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Control of blood pressure, the use of angiotensin-converting-enzyme (ACE) inhibitors, protein 
restriction, control of serum bicarbonate levels, anemia treatment, management of calcium and 
phosphate metabolism, control of dyslipidemia, vein preservation, immunization, psycological, socio-
economic and family support should be given to these patients [25, 23]. However, despite all these 
measures, patients with moderate CKD are more likely to die than to live long enough to develop severe  
kidney failure [26]. In fact, only about 2% of CKD patients progresses to end-stage renal disease [27].  
 
End-Stage Renal Disease 
 
 According to the United States Renal Data System 2011 Annual Data Report, the rate of new 
end-stage renal disease (ESRD) cases per million population has been relatively stable since 2000, and 
rose just 1.1 percent to 355 cases per million, in 2009 [28].  
ESRD is defined as an irreversible decline in kidney function that is severe enough to be fatal in 
the absense of dialysis or transplantation. ESRD is included under stage 5 of the National Kidney 
Foundation KDOQI classification of CKD or, irrespectively of GFR, if a patient requires renal replacement 
therapy (RRT) [18, 20]. Because of the degree of kidney impairment, ESRD may lead to severe fluid 
retention, anemia, disturbances of bone and mineral metabolism and increased risk of cardiovascular 
disease [29].  
 
Peritoneal dialysis as a renal replacement therapy 
 
Nowadays, support of renal function embraces a diverse selection of methods and clinical 
scenarios, and the option for hemodialysis (HD), peritoneal dialysis (PD) or renal transplantation is 
presented and discussed with the patient after his acceptation for RRT [30, 31].   
Clinical use of PD was delayed until the 1940s with the presentation of four cases by Dr. Jacob 
Fine and colleagues at the American Surgical Association and its widespread use as a chronic treatment 
for patients with ESRD has become a reality since 1976 [32, 33].  
PD is a RRT technique based on the use of the peritoneal membrane, a special “dialysis” 
membrane that separates two fluid containing compartments: the peritoneal cavity and the peritoneal 
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capillaries [20]. The process involves the insertion of a long term peritoneal catheter that provides 
access to the peritoneal cavity and through which a dialysis solution is infused. After a period of time 
(dwell time) that fluid is removed and substituted by fresh dialysis solution [24]. Peritoneal dialysis may 
be carried clinically as continuous ambulatory peritoneal dialysis (CAPD), automated peritoneal dialysis 
(APD) or a combination of both [34, 35]. In CAPD, the dialysis solution is characteristically changed three 
to four times a day. The substitution of the spent dialysate by the fresh dialysis solution is performed 
manually. In APD exchanges are performed by an automated cycler that allows a series of shorter 
exchange cycles, usually at night time [24]. 
The singular features of the peritoneal membrane [20] enable the successful removal of salt 
and water, as well as nitrogenous wastes that accumulate in the blood stream due to ESRD, such as 
urea, creatinine and other toxic materials [20, 3]. This water and solute clearance can be achieved by 
two physiological processes: diffusion and convection. Diffusion corresponds to the movement of 
solutes from a place where their concentration is higher (blood stream) to a place where it is lower 
(abdominal cavity). Convection which is generated by ultrafiltration, corresponds to the clearance of 
water from the blood to the peritoneal cavity and depends on the osmotic agent of the dialysis solution, 
which is traditionally dextrose [3, 24]. Dialysis solution (also called dialysate) usually contains sodium, 
chloride and lactate or bicarbonate and high concentration of an osmotic agent, dextrose, which turns 
the dialysate hyperosmolar. The volume of this solution that is infused into the peritoneal cavity during 
a peritoneal dialysis course generally ranges from 1.5 to 3 L [24, 20]. 
The rate of transcapillary ultrafiltration can be increased by increasing dextrose concentration 
in the dialysate and that rate is higher when the dialysate is instilled into the peritoneal cavity. Over the 
duration of the dwell, the osmotic gradient disappears and transcapillary ultrafiltration drops, because 
dextrose is absorbed into the systemic blood stream and the dialysate is diluted by the ultrafiltrate [3]. 
According to the transfer rates of dextrose and creatinine across the peritoneal membrane, patients can 
be classified as low, low average, high average and high transporters [24]. High or high average 
transporters are more likely to absorb more dextrose and loose efficiency of ultrafiltration with longer 
dwell times using dextrose-based dialysate. They can get advantage by performing shorter dwell times 
or by using alternative agents, like icodextrin [24, 3]. 
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Therefore, the clearance of water and solutes depends on the volume of dialysate, type of 
osmotic agent, concentration of the osmotic agent, regularity and duration of dwell’s exchange and 
peritoneal transport rate of each patient [20, 3]. These parameters can be adapted to each CKD patient 
regarding its particular features, so that PD can be optimized and selected for further purposes other 
than RRT. 
In many countries PD has been shown to be less expensive than, or having at least similar costs 
to in center-HD, as the initial RRT modality [36, 37]. Compared to in center-HD, PD has similar survival 
rates, similar or better quality of life and maintains superior preservation of residual renal function. In 
what it concerns to infectious complications, there is no apparent difference between PD and HD [2, 38-
40]. Apparently only HD is associated with bacteremia, mostly related to the central venous catheters, 
especially in the first 90 days of therapy, while PD infections seldom result in bacteremia [38, 1]. An 
important disadvantage of PD is the high rate of procedure failure, leading a large amount of patients to 
switch from PD to HD [39]. This happens mainly for reasons related to peritoneal infections due to 
Staphylococcus aureus, Pseudomonas aeruginosa or fungi, peritoneal catheter complications, decline in 
residual renal function, and changes in the peritoneal membrane (thickening and neovascularization) 
due to chronic treatment [41].      
PD as a RRT for the treatment of CKD may be started in several clinical contexts such as 
intractable fluid overload, intractable hyperkalemia, malnutrition related to uremia, uremic neurological 
dysfunction, uremic serositis, declining functional status otherwise unexplained and prediction of access 
difficulty [18].  
 
Clinical use of peritoneal dialysis beyond end-stage-renal disease 
 
 Although ESRD remains the major indication for the use of PD,  this RRT has the potential to be 
used in the management of other clinical disorders like congestive heart failure (CHF), pancreatitis, 
psoriasis, hypothermia, ascites, and administration of intraperitoneal chemotherapy, with or without 
concomitant ESRD [42, 4].   
Peritoneal lavage was purposed as a treatment option for patients with acute pancreatitis 
aiming the removal of toxic solutes from the peritoneal cavity and expecting that, by doing so, they 
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wouldn’t have access to the systemic circulation.  Five controlled trials were performed in patients with 
acute pancreatitis in order to evaluate the role of peritoneal lavage through PD on the morbidity and 
mortality of these patients. Two of them suggested a positive effect on morbidity and early mortality 
while three other failed to establish a reduction at this level [42].   
The finding that severe psoriasis in ESRD patients achieved complete remission when dialysis 
was initiated has triggered the interest in the use of PD for patients with incapacitating psoriasis, even in 
the absence of significant renal dysfunction. The first randomized cross-over study proved the straight 
role of PD in the induction of clinical remission [42]. However, subsequent controlled studies performed 
in larger groups of patients showed both therapeutic successes and failures [43]. It seemed that PD 
could clear psoriatic plaques in an unpredictable and small amount of patients [43]. Because of the 
uncertain clinical results obtained with PD and its potential risks, as well as the development of better 
noninvasive medical therapies for the management of psoriasis, PD has been held for more refractory 
cases in which standard and rescue therapy have failed [43, 42].        
In multiple clinical contexts, patients with severe hypothermia (<30°C) are indicated for active 
core warming and PD was reported as a feasible method to provide it. The lack of controlled trials of the 
different rewarming modalities in humans made PD application in this area difficult and no secure 
clinical indications for its use are still available [42].  
Intraperitoneal chemotherapy has been used for more than four decades to palliate patients 
who develop peritoneal carcinomatosis. Chemotherapy must be administered using the dialysate as a 
carrier solution, what causes two major difficulties. It induces ultrafiltration in patients with normal 
renal function and it demands frequent exchanges to preserve therapeutic drug concentration. The first 
randomized trial comparing intraperitoneal to intravenous therapy in patients with high-risk colon 
cancer showed no survival benefit. However, randomized controlled trials of patients with gastric cancer 
with positive nodes and ovarian cancer have demonstrated an evident survival advantage of 
intraperitoneal chemotherapy when compared to intravenous chemotherapy [42]. 
The applicability of PD in congestive heart failure and ascites will be discussed in the following 
chapters.  
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The role of peritoneal dialysis in the treatment of congestive heart failure 
 
 Nowadays, CHF is a growing health problem in developed countries and is associated with high 
mortality rates, high comorbidities and high hospitalization and readmission rates [5, 6]. In 2010, 6.6 
million (2.8%) USA citizens older than 18 suffered from heart failure, and heart failure incidence 
approached 10 per 1000 population after 65 years of age [6]. Even in patients with well managed 
disease, CHF can become lethal, particularly when it becomes resistant to standard treatment [5, 8].  
As the European Society of Cardiology (ESC) states,  “heart failure can be defined as an 
abnormality of cardiac structure or function leading to failure of the heart to deliver oxygen at a rate 
commensurate with the requirements of the metabolizing tissues, despite normal filling pressures (or 
only at the expense of increased filling pressures)” [7]. There are two major scales to classify CHF, the 
New York Heart Association (NYHA) classification based on the severity of symptoms and the level of 
physical activity and the American College of Cardiology/American Heart Association (ACC/AHA) based 
on structure and damage of cardiac muscle (table II) [7, 44]. 
 The presence or the development of renal dysfunction is a common clinical feature during the 
course of CHF, giving rise to the so-called “Cardiorenal Syndrome” (CRS) [45]. It is also frequently 
observed that decompensated CHF results in acute worsening of renal function [46]. There are several 
pathophysiological mechanisms responsible for the development of CHF that can also affect renal, 
hemodynamic, neurohormonal and immunological function [47]. As a consequence of the reduced renal 
perfusion in the presence of CHF, there is an increased and sustained activation of the renin-
angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) accompanied by 
vasopressin release that together may cause systemic vasoconstriction and water and sodium retention, 
with concomitant fluid accumulation. This neurohormonal activation also causes left ventricular 
hypertrophy, myocardial apoptosis and fibrosis, and deterioration of both heart and renal function, the 
latter due to glomerulosclerosis and tubulointerstitial fibrosis related to promitogenic and 
proinflammatory actions in the renal tissue. The progressive damage to the cardiac and renal tissue, 
allied to the common group of risk factors - hypertension, diabetes mellitus and atherosclerosis (shared 
by both diseases) - can help to explain the high frequency of the coexistence of both clinical entities [47-
50]. 
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Standard treatment of congestive heart failure and treatment of refractory congestive heart failure  
 
The three goals of the treatment of CHF patients are to improve symptoms, prolong survival 
and to prevent or slow the progression of the disease [3, 7]. It is important that the treatment includes 
lifestyle and diet issues, especially in what concerns to salt and water restriction, in order to limit 
ventricular remodeling and neurohormonal activation.  Because the major cause of hospitalization in 
CHF is fluid overload, causing acute cardiac decompensation, and only 5% of the causes are related to 
reduced cardiac output, the control of sodium and water balance assumes a cardinal importance in the 
treatment of these patients  [47]. The standard pharmacological therapies include RAAS inhibitors and 
beta-blockers (which have shown a significant impact on disease progression, mortality and morbidity), 
conventional diuretics – mainly loop diuretics – and digitalis [44, 7].  
Refractory congestive heart failure is a syndrome characterized by the inability to improve 
symptoms or by the recurrence of heart failure despite optimal medical therapy [44]. One important 
cause of such treatment failure is diuretic resistance. It is considered optimal therapy with diuretics the 
use of intravenous loop diuretics in the maximal dose tolerated by the patient, supported by successive 
blocking of the nephron by other drugs. Such patients, despite fluid and salt restrictions and optimal 
diuretic therapy, sustain a status of fluid overload [51]. The majority of patients with CHF resistant to 
the conventional therapy probably have an underlying cardiorenal syndrome. These patients may 
experience symptoms at rest and require frequent or prolonged hospitalizations for rigorous controlling. 
The various symptoms presented in these cases can be attributed to the retention of salt and water that 
produces a state of hypervolemia, often developing hyponatremia, hyperkalemia and azotemia [5, 3, 
44]. The long-term use of diuretics causes a decline in the magnitude of natriuresis because of 
tubuloglomerular feedback activation. The increased sodium delivery to the juxtaglomerular apparatus 
activates a maladaptative response in which natriuresis is attenuated and sodium homeostasis is 
maintained at the expense of the stimulation of renin secretion, enhanced RAAS activity and stimulation 
of SNS [8, 50]. Some alternative therapies to improve sodium and water excretion have become recently 
available such as antidiuretic hormone receptor antagonists, natriuretic peptides agonists, adenosine 
receptor antagonists and ultrafiltration techniques [8].  
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Ultrafiltration techniques:  the role of peritoneal dialysis 
 
Techniques complementary to conservative treatment of fluid overload comprise isolated 
ultrafiltration or hemodiafiltration with extracorporeal devices or peritoneal dialysis [51]. In acute 
decompensated CHF and short-term management of refractory CHF extracorporeal therapies are used 
more often. For long-term treatment of CHF resistant to diuretics peritoneal dialysis is proposed, as a 
home-based procedure [51].   
 Based on studies about the treatment of acute decompensated heart failure, ultrafiltration 
techniques have been proposed as alternative therapies for these cases, because they present several 
advantages. When compared to diuretics, ultrafiltration techniques allow faster fluid removal and 
improvement of symptoms, increased sodium removal, decreased risk of electrolyte derangements, 
diminished RAAS and SNS activation, removal of pro-inflammatory cytokines, possible restoration of 
diuretic responsiveness, decreased re-hospitalization rates and shortened length of hospitalization and 
decreased risk of worsening renal function [9, 8]. 
 Faster fluid removal can reduce the risk of cardiac ischemia, arrhythmias, additional clinical 
decompensations and the need for clinical close watch [8]. For the same fluid volume extracted by 
ultrafiltration techniques, greater amounts of sodium are removed, when compared to diuretics (the 
urine produced by loop diuretics is hypotonic in relation to plasma, while the ultrafiltrate is iso-osmotic 
and isonatremic), dodging the higher sodium delivery to the distal nephron. Theoretically, this can avoid 
the tubuloglomerular feedback mechanism, explaining the lack of activation of RAAS and SNS [8, 9, 52].  
Loop diuretics can originate hypokalemia and metabolic alkalosis and both may be less frequent during 
ultrafiltration therapy [52]. Through convection, ultrafiltration enables the clearance of cytokines-sized 
molecules, which is an hypothetical advantage because it may allow the removal of some interleukins or 
tumor necrosis factors, that play an adverse role in the pathophysiology of CHF [8]. The ultrafiltration 
versus intravenous diuretics for patients hospitalized for acute decompensated congestive heart failure 
(UNLOAD) trial included 200 patients with acute decompensated heart failure randomized to 
ultrafiltration or intravenous diuretics willing to compare both groups. It showed greater weight and 
fluid loss and lower incidence of re-hospitalization in the group of patients randomized for 
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ultrafiltration, but unfortunately found no difference in the levels of creatinine and  mortality between 
the two groups [52]. 
In patients with refractory congestive heart failure with acute volume overload resistant to 
therapy, short-term peritoneal ultrafiltration is associated with improvement of hyponatremia, 
impairment in plasma volume and pulmonary capillary wedge and re-establishment of diuretic 
responsiveness. Nevertheless, the ease of use of extracorporeal ultrafiltration and their notable benefits 
supplanted the inpatient use of PD for acute fluid overload associated with refractory CHF [3]. PD can be 
an option in long-term treatment of refractory CHF having some advantages over extracorporeal 
ultrafiltration such as higher preservation of RRF, continuous ultrafiltration, better hemodynamic 
stability, better removal of medium sized-molecules, sodium removal with maintenance of 
normonatremia and diminished systemic inflammation [47]. Besides all of that, PD as a home-based 
therapy provides the clinical and psychological benefits of home dialysis with no need for complex 
equipment or hospital resources, resulting in better quality of life for these patients [51, 47]. Despite the 
benefits of performing the technique at home, a large amount of older patients are incapable to 
undergo PD at home without some kind of support [41].  
Quite a few reports highlight the value of PD as an approach to  provide daily, continuous, slow 
ultrafiltration in patients with CHF [53-56]. Patients with treatment-resistant CHF have a lot of 
associated morbidities, a high rate of hospitalizations related to fluid overload exasperation and impose 
a large financial burden. While extracorporeal ultrafiltration requires patients to visit the hospital and 
carries the risk of hypotension, PD can be performed at home and has no risk of associated hypotension, 
which makes this approach more convenient [3]. Besides its possible effect in the restoration of diuretic 
responsiveness, PD can work as a bridge therapy in patients waiting for procedures such as valve 
replacement or cardiac transplantation and as an ambulatory palliative therapy when definitive therapy 
is not possible. The latter indication is related to the capacity of PD to improve symptoms and exercise 
tolerance (improving functional status), to preserve residual renal function when compared to 
extracorporeal ultrafiltration, to significantly reduce the number of hospital days per patient and to 
improve quality of life [3]. On the other hand, PD appears not to modify the natural progression of CHF  
and a significant effect on the survival of patients is also questionable [3]. Apart from the age, 
individuals diverge extremely in the physiological response to dialysis treatment [18]. 
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 Several studies support the potential roles of PD in the treatment of CHF. Nunez et al 
conducted a prospective study with a follow-up period of 2.5 years including 25 participants with 
advanced refractory CHF treated with CAPD, and concluded that they had a significant improvement in 
symptoms, physical performance, quality of life and biochemical profile, marked reduction in the 
number of days of hospitalization, an acceptable rate of side effects (21 episodes of peritonitis, 15 
responding to ambulatory antimicrobial therapy) and a significant decrease in serum urea, finding no 
favorable changes in cardiac biomarkers, serum creatinine and estimated glomerular filtration rate 
(eGFR) [55]. Cnossen et al studied 24 patients for a period of 10 years with primary treatment-resistant 
CHF complicated by severe renal failure (CRS type 2) treated with CAPD and reached three major 
findings: survival in treatment-resistant CHF patients complicated by severe renal failure is extremely 
inconstant after starting PD (mean survival of 1.0 year); age and diabetes mellitus, but not left 
ventricular ejection fraction (LVEF), seemed to be prognostic factors for the 1 year survival rate and, at 
last, patients who survived more than 1 year had a reduction in hospitalization rate regardless of cause 
[53]. Gotloib et al performed a prospective, non-randomized study of 20 patients with treatment-
resistant CHF (NYHA class IV) that received APD (3 sessions/week 8h each) with the duration of 3 years. 
He found an improvement in cardiac work index and a mortality rate of 10% at 1 year, which was 
significantly less than the expected, based on the comorbidity scores of these patients [57]. Nakayama 
et al ran a prospective study with a median follow-up of 26.5 months with 12 elderly participants. All 
patients improved their NYHA functional class and reduced dosages of diuretics were required. 
Significant improvements in hemoglobin count and in end-diastolic left ventricular diameter were also 
achieved [54]. Koch et al performed PD treatment (in this case center-based nocturnal intermittent APD, 
3 times a week for 12h each session) in 118 patients with refractory CHF for a mean time of follow-up of 
1 year. They demonstrated that PD improves symptoms of severe CHF patients with CKD, with NYHA 
class improving significantly in patients with more than 6 months survival. It was also verified that PD 
treatment was well stood without important complications and with a low number of technique related 
deaths. However, even with the implementation of the PD treatment, mortality persisted significantly 
high (mean survival of 1.72 years) [56]. 
16 
 
One of the main conclusions to take from all these data is that there is an urgent need to 
conduct controlled trials with larger populations, in order to define subgroups of CHF patients who may 
benefit from PD and to establish clinical criteria for starting PD. 
From my perspective, for as much as CHF can be controlled with the standard treatment, 
invasive methods must be avoided. In the acute context of cardiac decompensation due to fluid 
overload, PD must be weighed since it provides faster fluid removal and improvement of the symptoms, 
especially if a scenario of diuretic resistance is consider. Upon the establishment of refractory 
congestive heart failure, patients could be evaluated on their ability to perform PD at home. This could 
represent a way to improve their congestive symptoms and to reestablish the diuretic responsiveness 
once had, but just as important is the opportunity to perform the technique at home, improving the 
quality of life of these patients, as already so impaired by the disease itself. Likewise, patients who 
develop cardiorenal syndrome can benefit from PD, either for the fluid excess component, either for the 
renal dysfunction component.   
 
The role of peritoneal dialysis in the treatment of ascites and hepatorenal syndrome 
 
Cirrhosis is the end-stage of all chronic liver disease and ascites is a frequent complication in 
this setting [11]. According to a 2011 vital statistics report, chronic liver disease (CLD) or cirrhosis were 
the 12
th
 leading cause of death in the United States (with a death rate of 10.8) and were the 5
th
 leading 
cause of dead among the population of adults aged 45-64 years [58]. The prognosis in cirrhosis depends 
on a number of factors, such as etiology and severity of CLD, the presence of complications and the type 
of associated comorbidities [59]. 
The development of cirrhosis happens as the hepatic fibrosis progresses. Cirrhosis is ultimately 
characterized by transformed liver structure and by the establishment of regenerative nodules [24]. This 
entire process can be divided in two phases. One is called compensated phase, with a prevailing 
asymptomatic profile and the other one is called decompensated phase, a rapidly progressive state 
manifested by the development of portal hypertension and liver dysfunction [11]. 
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To assess the liver disease severity, many clinicians use the traditional scale Child-Pugh Score 
that combines albumin, bilirubin, prothrombin time and the presence of ascites or encephalopathy. This 
grading score is represented below (table III) [59]. A total score ≤6 is considered grade A, 7-9 is grade B 
and ≥10 is grade C. These grades correspond to a one-year survival rates of 100%, 80% and 45%, 
respectively [59]. 
Ascites, parameter of the Child-Pugh classification system, is the most frequent complication of 
cirrhosis and the one that more commonly leads to hospital admissions [60]. If the underlying cause of 
cirrhosis is left untreated, there is a risk for developing ascites of nearly 60% at 10 years [11]. 
The International Ascites Club has recently suggested a classification system for ascites. It 
establishes 3 grades. Grade 1 corresponds to mild ascites only detectable by imaging tests (ultrasound), 
grade 2 corresponds to moderate ascites and manifesting as symmetrical abdominal distension and 
grade 3 corresponds to severe ascites with notable abdominal distension [61]. 
Cirrhotic patients are susceptible to a number of others complications that determine a poor 
prognosis and that are associated with a lower life expectancy [60, 13]. The other two main 
complications of cirrhosis beyond ascites are encephalopathy and variceal hemorrhage [60]. 
The pathogenesis of ascites is related to two major mechanisms: portal hypertension and renal 
sodium retention. As the disease progresses, there is an increased resistance to portal flow at the 
sinusoidal capillaries leading to the development of hypertension at this level [12, 60, 14]. That 
increased pressure is transmitted backwards to the splanchnic capillaries resulting in the pooling of 
blood in this area. Sinusoidal hypertension is also related to splanchnic arterial vasodilation and that 
process is thought to be mediated essentially by nitric oxide (NO), although other vasodilators can be 
involved, such as prostacyclin and other  prostaglandins [17, 14]. NO increased production is mainly due 
to shear-stress-induced upregulation of endothelial NO synthase [14]. Powerful hepatic and splanchnic 
angiogenesis also develop due to the great levels of proangiogenic substances, such as vascular 
endothelial  growth factor (VEGF) and platelet-derived growth factor (PDGF) [14]. The outcome is a 
decrease in peripheral vascular resistances and a reduction in effective blood volume. Reduced effective 
arterial blood volume leads to increased activity of RAAS and SNS and to the nonosmotic release of 
vasopressin [12, 14]. These changes lead ultimately to vasoconstriction of extraesplanchnic beds, 
including the renal and cerebral circulations [14].  
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The second mechanism of sodium retention is also related to portal hypertension, but the renal 
initiator of that retention is still unknown. In this mechanism, sodium retention precedes ascites 
formation and appears not to be related to the reduction in arterial blood volume. However, continued 
sodium retention is necessary for ascites formation, since increased hydrostatic pressure alone cannot 
produce ascites. These hemodynamic and renal alterations determine a nonstop leakage of fluid from 
sinusoidal and splanchnic capillaries into the interstitial space, overcoming the lymphatic absorption 
capacity and leading to a progressive accumulation of fluid into the peritoneal cavity [12]. All these 
changes continue to develop as cirrhotic patients progress from pre-ascites to responsive ascites then to 
refractory ascites and finally to hepatorenal syndrome (HRS) [14]. Cirrhosis is, overall, the cause of 75% 
cases of ascites [61]. 
 
 
Standard treatment of ascites and refractory ascites in cirrhosis 
 
The aim of treatment in patients with ascites due to cirrhosis involves correcting the underlying 
pathophysiological processes of the liver disease that drive to ascites formation [13]. It is important to 
improve sodium balance minimizing water and sodium retention and to improve circulatory function 
until liver transplantation is available or until cirrhosis runs its regular course [13, 61]. This can be done 
either by reducing dietary sodium intake or by increasing renal sodium excretion [61]. Dietary sodium 
restriction implies a diet with low-sodium substances and dietician counseling and family support may 
be necessary in order to help patients to adhere to it [13]. A sodium intake of 2g/day is recommended 
(88mmol/day) [60]. Renal sodium excretion can be achieved by blocking sodium reabsorption along the 
nephron using diuretics. Therapy typically starts with an aldosterone antagonist, usually spironolactone, 
but if the patient does not achieve an adequate response, a loop diuretic can be added [13].  The rate of 
weight loss is 1kg/day (maximum) when ascites and peripheral edema are present and 0.5 kg/day if 
patient only have ascites and no edema [61, 60].  
The largest, multicenter and randomized controlled trial performed in patients with ascites due 
to cirrhosis stated that acceptable levels of ascites volume could be achieved in up to 90% of the 
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patients treated with dietary sodium restriction allied to a dual diuretic regimen combining 
spironolactone and  furosemide [60]. 
   Of all patients with ascites, proximately 5 to 10% develop a condition called refractory ascites 
[61]. According to the International Ascites Club, refractory ascites is defined as ascites that cannot be 
mobilized or whose early recurrence cannot be satisfactorily avoided by medical therapy. It can be 
divided into two subgroups: diuretic-resistant ascites and diuretic-intractable ascites (patients who 
cannot stand diuretic therapy because of the development of complications) [61, 13]. The International 
Ascites Club proposed the diagnostic criteria  for refractory ascites (table IV) [61]. 
For patients with refractory ascites either unresponsive or intolerant to medical therapy, 
paracentesis and insertion of a transjugular intrahepatic portosystemic shunt (TIPS) are optional 
interventions. Unless there is any specific contraindication, all these patients should be considered for 
liver transplantation as well [13].  
When patients develop refractory ascites, paracentesis is still the first-line treatment and it may 
have to be performed repeatedly because of the reappearance of tense (or massive) ascites [12]. 
Paracentesis can also help to accelerate the resolution of large-volume ascites and to allow easier 
ultrasound investigation in patients with massive ascites [61]. There are no absolute contraindications to 
the use of this technique [12]. Nevertheless, paracentesis should be avoided in cases of disseminated 
intravascular coagulation [62] and should be done with caution when intra-abdominal adhesions or 
urinary bladder distension are present [12]. The most common complications are post-paracentesis 
effective hypovolemia and renal impairment, an incident called paracentesis-induced circulatory 
dysfunction (PICD) [61, 12]. Ascitic fluid removal causes a decrease in intra-abdominal pressure, 
improving blood return to the heart. This develops a hyperkinetic circulation causing shear stress to the 
peripheral vasculature [12]. Consequentially there is an extra decrease in effective arterial blood volume    
recognized by the raise in the SNS and RAAS activity, placing the patient at risk of renal dysfunction [12, 
13]. PICD diagnosis is based on an increase in plasma renin activity (PRA) > 50% of the pre-paracentesis 
value to a final level of > 4 ng/ml/h [13]. Reasonably, paracentesis followed by plasma expansion has 
been suggested in order to prevent PICD. A large multicenter randomized control trial compared the use 
of albumin to the use of synthetic complexes as plasma expanders and found that albumin was superior 
for that purpose [12].  
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Some patients may require repeated paracentesis which can become intolerable [61]. In this 
situation, TIPS is another therapy option for refractory ascites that functions as a side-to-side porto-
systemic shunt. It lowers intrahepatic portal pressure and improves sodium excretion and response to 
diuretics, decreasing ascites recurrence rates [63, 12]. TIPS may be indicated in patients that do not 
tolerate/should avoid paracentesis or when this technique is ineffective [61]. The use of this treatment 
modality is limited due to high frequency of complications such as capsule puncture, intra-abdominal 
bleeding, shunt thrombosis and stenosis, hepatic encephalopathy and precipitation of cardiac failure in 
patients with cardiac disease [61]. Wong et al states that 5 randomized controlled trials took place in 
order to compare TIPS to large volume paracentesis (LVP) as a treatment option for ascites.  In all of 
those studies, TIPS proved to be more effective than LVP in what concerns to the management of the 
ascites, despite causing more events of hepatic encephalopathy [13]. 
Any patient with refractory ascites related to cirrhosis should be considered as a potential 
recipient of a liver transplant, because that is the only procedure that rectifies the impaired liver 
function and the high portal pressure, effectively improving survival [13, 63].      
 
Hepatorenal syndrome 
 
Patients with advanced cirrhosis and ascites resulting from end-stage liver disease can develop 
a serious complication named hepatorenal syndrome (HRS), especially in cases where an important 
circulatory dysfunction is present [16].    
The prevalence of renal failure along with hepatic cirrhosis is not known, but there is a clear 
growth in the frequency of the occurrence of this association due to the increasing prevalence of both 
diseases [4].  The prevalence of HRS in patients with liver cirrhosis with ascites is 18% at 1 year, reaching 
39% at 5 years. Nearly half of all the HRS cases have a precipitating factor. Between those factors, 
frequently are recognized bacterial infections, gastrointestinal hemorrhage and paracentesis with a 
frequency of 57%, 36% and 7%, respectively [15, 16].  
The pathophysiology of the  hepatorenal syndrome corresponds to the most advanced phase of 
hemodynamic dysfunction that starts early in the course of end-stage liver disease [14]. At this phase, 
patients develop arterial hypotension due to additional reduction of the peripheral vascular resistances. 
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With cirrhosis and vasodilation progression, cardiac output becomes insufficient, contributing to renal 
hypoperfusion [12, 16]. These evidences suggest that a hyperdynamic circulation is crucial to the 
maintenance of a normal blood volume and for an appropriate renal perfusion in liver disease. 
Consequently, cardiac output failure leads to effective hypovolemia causing renal hypoperfusion and 
HRS [16].   
According to the speed of onset and to the clinical significance, HRS can be classified as two 
distinguishable types: type 1 and type 2. Type 1 corresponds to a sudden deterioration of kidney 
function that usually follows a precipitating event and where the serum creatinine doubles in 2 weeks to 
a level higher than 2.5 mg/dL. It presents as acute renal failure. Type 2 corresponds to a progressive 
decline in kidney function, developing over weeks to months. It represents the most advanced stage of 
hemodynamic dysfunction that develops in cirrhotic patients and its clinical pattern is refractory ascites 
[14, 17, 15]. The diagnostic criteria of HRS have been recently revised by the International Ascites Club 
(table V) [16]. 
HRS has a very poor prognosis, being easier to prevent than to treat [14]. Treatment should 
start as soon as possible [17]. Therapeutic interventions can be implemented at three different levels: 
specific treatment of HRS, treatment of renal failure or therapy of liver failure [17]. The latter can be 
solved with liver transplantation, the treatment of choice for type 1 and type 2 HRS [16]. However, liver 
transplant is associated to higher morbidity in HRS patients when comparing to those without the 
syndrome [16]. 
First-line treatment specific for HRS is the use of albumin, accompanying every single 
pharmacological intervention in HRS patients [17]. The second component of the treatment is the use of 
vasoconstrictors, based on the knowledge that splanchnic vasodilation plays an important role in the 
pathogenesis of HRS [64], with terlipressin being the most studied compound, mostly in type 1 HRS [16]. 
TIPS is an option for the specific treatment of HRS and it may additionally stabilize renal function in 
patients successfully treated with vasoconstrictors, despite its low applicability [16].            
 Treatment of kidney failure includes RRT and patients may benefit from an early start of that 
technique [17]. The indications for RRT are the same in HRS patients as for non-cirrhotic patients with 
acute renal failure: volume issues, acidosis control, uremic complications and electrolyte disorders 
(hyperkalemia) [14, 65]. However, because of the poor prognosis  in HRS patients, RRT is kept for 
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patients who are considered candidates for orthotopic liver transplant (OLT) or who are being assessed 
for OLT [65]. Survival after OLT is good in patients receiving RRT, but is worse than in those without 
renal failure who undergo liver transplant [65].  Wong et al studied 102 patients receiving RRT for acute 
kidney failure who were waiting for OLT and survival rate was only 33% [66]. This can be partially due to 
the primary liver disease and to the effort of providing RRT to patients who suffer from hypotension, 
coagulopathy and thrombocytopenia [65].  Although RRT can work as a bridge to patients waiting for 
OLT, more controlled studies should be done and the several RRT techniques could be compared, due to 
the particular features of each of them.     
 
Renal replacement therapy in end-stage renal disease patients with liver cirrhosis and ascites 
 
 Patients with CLD can have renal disease that progresses to ESRD. Mutually, patients with ESRD 
can develop liver disease and cirrhosis with ascites [4]. The incidence of ascites in ESRD patients varies 
from 0.7 to 20% [67].  
The optimal time to start dialysis in these patients is not easy to define, since they share 
symptoms as weight loss, anorexia, etc., which could be due to uremia or liver disease [4]. Moreover, 
the over-estimation of the GFR can lead to the attribution of the symptoms more to the liver disease 
than to the uremia, delaying appropriate start of RRT [68]. 
No clinical trials that evaluate the impact of the different dialysis modalities for ESRD in 
cirrhotic patients have yet been performed [4] and the few clinical trials that have been carried out were 
designed to  assess the impact of HD in cirrhotic patients with acute renal failure [68].  
One of the major limitations of HD in cirrhotic patients is intra-dialysis hypotension. Cirrhosis is 
associated with reduced peripheral vascular resistance that is related partially with increased circulating 
levels of nitric oxide. As described above, as cirrhosis progresses, chronic hypotension develops. The 
sudden decrease in intravascular volume by ultrafiltration during HD may further intensify the level of 
hypotension [68, 4]. There is also an increased risk of hemorrhage in cirrhotic patients due to 
coagulation disorders and platelet abnormalities, causing problems with HD, especially in patients with 
an arteriovenous access. In the absence of studies regarding the use of anticoagulation in cirrhotic 
patients the aim should be its minimal usage [4, 68]. By the other hand, accurate measurement of 
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dialysis adequacy can be difficult in patients with ascites undergoing HD [68]. Ascites creates a pool of 
fluid rich in urea inside the abdominal cavity. After dialysis it can take some time until urea level 
equilibrates and urea level measurement right after dialysis can be misleadingly small and urea 
reduction ratio can be overestimated [4]. Another complication of HD is the quick shift in the osmolarity 
and electrolyte levels that can increase cerebral water content, increasing the risk of encephalopathy 
[4]. 
PD, as a continuous treatment, can offer quite a few advantages over HD in cirrhotic patients. 
[4]. Because PD is a slow and continuous dialysis technique, it is hemodynamically superior to HD and it 
becomes better tolerated in patients with cirrhosis and ascites [4]. This hemodynamic improved 
tolerance reduced the episodes of hypotension in PD when compared to HD dialysis [4, 67]. PD also 
enables a continuous depuration of solutes, caloric input of glucose and amino acids for patients with 
malnutrition and anorexia, and the convenient avoidance of anticoagulation treatment [4].  
As known, evacuation paracentesis is the most effective treatment for the management of 
severe ascites. Given that PD is a slow and continuous dialysis and volume loss technique, it can 
simulate a daily basis paracentesis procedure and can  present itself as an alternative  to the 
management of these patients, even for long periods of time [67]. Thereby, another PD application may 
be the progressive draining of the ascitic fluid in cirrhotic patients [4]. This procedure has also been 
successfully used in patients with ESRD that develop ascites due to heart failure, fulminant hepatic 
failure and renal failure (all cirrhotic unrelated causes of ascites) [4].  
However, the use of PD has been limited by the possibility of excessive bleeding due to catheter 
placement, inadequate ultrafiltration and solute removal in the presence of ascites, higher rates of 
peritonitis and protein loss into the dialysate have limited PD use [68, 4]. These limitations had 
apparently no significant impact in a study from De Vecchi et al that compared 21 cirrhotic patients to 
41 non-cirrhotic patients on PD and found that the survival was similar in the two groups [4].   
 In my perspective, patients that develop HRS or patients that have cirrhosis/ascites secondarily 
to renal dysfunction would benefit from PD. Since cirrhosis is associated with a state of chronic 
hypotension, the more hemodynamic stability of PD, when compared to HD, can present this technique 
as a more favorable approach. Patients that require repeated paracentesis could also benefit from PD 
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since they could do daily basis paracentesis at home, what could be more comfortable for them, 
especially if the treatment is necessary for a long period of time.    
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Conclusion 
 
Despite the fact that PD is mainly considered a RRT, this technique can also be used for the 
treatment of several non-renal conditions.  Renal dysfunction is common in CHF and carries a bad 
prognosis, in these patients. Besides that, some patients develop resistance to standard medical 
treatment and, in this situation, ultrafiltration techniques have been effective in improving volume 
overload. PD appears as a viable ambulatory ultrafiltration modality and it may even help to restore the 
effectiveness of diuretics in treatment-resistant CHF.  
Treatment of patients with HRS or concomitant CLD (with ascites) and CKD is complex. PD as a 
RRT in this context is a valuable alternative with potential benefits over HD, such as improved 
hemodynamic and lower risk of hemorrhage. Since intermittent evacuation paracentesis is the 
treatment of choice for ascites in cirrhotic patients, the slow and continuous drainage of peritoneal fluid 
through PD is comparable to the typical treatment, even in a long-term basis.  
A particular significant advantage related to PD is the possibility to be performed at home, 
minimizing the interference with patient’s daily activities, improving their quality of life as they learn 
how to deal with a chronic and sometimes debilitating disease. Thus, if the patients are able to perform 
the necessary procedures this potential advantage becomes real, providing good therapeutic efficacy 
with better life quality. 
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Table I. The five stages of chronic kidney diasease are described in the table, according to the KDOQI 
guidelines. 
Adapted from KDOQI (Kidney Disease Outcome Quality Iniciative) Clinical Practice Guidelines for Chronic 
Kidney Disease (CKD) [18]. 
  
CKD stages Description GFR (ml/min/1.73m
2
) 
1 Kidney damage with normal or 
↑GFR 
≥90 
2 Kidney damage with mild ↓GFR 60-89 
3 Moderate ↓ GFR 30-59 
4 Severe ↓ GFR 15-29 
5 Kidney Failure <15 (or dialysis) 
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Table II. Describes the classification criteria from the American College of Cardiology/American Heart   
ACC/AHA  NYHA  
Stage A Patients at high risk of developing HF 
because of the presence of conditions 
which are strongly associated with the 
development of HF. Such patients 
have no identified structural or 
functional abnormalities of the 
pericardium, myocardium, or cardiac 
valves and have never shown signs or 
symptoms of HF. 
Class I No limitation of physical activity. 
Ordinary physical activity does not cause 
undue breathlessness, fatigue or 
palpitations. 
Stage B Patients who have developed 
structural heart disease that is strongly 
associated with the development of HF 
but who have never shown signs or 
symptoms of HF. 
Class II Slight limitation of physical activity. 
Comfortable at rest, but ordinary 
physical activity results in undue 
breathlessness, fatigue or palpitations. 
Stage C Patients who have current or prior 
symptoms of HF associated with 
underlying structural heart disease. 
Class III Marked limitation of physical activity. 
Comfortable at rest, but less than 
ordinary physical activity results in 
undue breathlessness, fatigue, or 
palpitations. 
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Table II (cont) 
Adapted from “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: 
The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European 
Society of Cardiology” [7] and from “ACC/AHA Guidelines for the Evaluation and Management of Chronic 
Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines” [44]. ESC – European Society of Cardiology; 
ACC/AHA - American College of Cardiology/American Heart Association 
 
 
 
 
 
 
 
 
 
 
 
Stage D Patients with advanced structural 
heart disease and marked symptoms 
of HF at rest despite maximal medical 
therapy and who require specialized 
interventions. 
Class IV Unable to carry on any physical activity 
without discomfort. Symptoms at rest 
can be present. If any physical activity is 
undertaken, discomfort is increased. 
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Table III. In the table are represented the parameters that constitute the Child-Pugh classification 
system for liver cirrhosis and their respective scores.  
Parameter Score 
 1 2 3 
Ascites Absent Mild Severe 
Bilirubin  <2 mg/dl 2-3 mg/dl >3 mg/dl 
Prothrobin time (INR) <4 sec. 4-6 sec. >6 sec. 
Albumin >3.5 g/dl 3.5-2.8 g/dl <2.8 g/dl 
Encephalopathy Absent Mild Severe 
Adapted from ”Management of liver cirrhosis between primary care and specialists”  [59] 
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Table IV. The Table represents the diagnostic criteria for refractory ascites, according to the 
International Ascites Club.  
Diagnostic criteria for refractory ascites 
1 - Treatment duration: Patients must be on intensive diuretic therapy (spironolactone 400 mg/d and 
furosemide 160 mg/d) for at least 1 week and on a salt-restricted diet of less than 90 mmol/day or 5.2 g 
of salt/day. 
2 - Lack of response: Mean weight loss of <0.8 kg over 4 days and urinary sodium output less than the 
sodium intake.  
3 - Early ascites recurrence: Reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization. 
4 - Diuretic-induced complications 
 Diuretic-induced hepatic encephalopathy - development of encephalopathy in the absence of 
any other precipitating factor. 
 Diuretic-induced renal impairment - increase of serum creatinine by >100% to a value >2 
mg/dl in patients with ascites responding to treatment. 
 Diuretic-induced hyponatremia - decrease of serum sodium by >10 mmol/L to a serum sodium 
of <125 mmol/L. 
 Diuretic induced hypo or hyperkalemia - change in serum potassium to <3 mmol/L or >6 
mmol/L despite appropriate measures.                
Adapted from “The management of ascites in cirrhosis: report on the consensus conference of the 
International Ascites Club” [61]. 
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Table V. The criteria for the diagnosis of hepatorenal syndrome are represented in the table, reflecting 
both the hepatic and renal component of the syndrome. 
Criteria for hepatorenal syndrome diagnosis 
Cirrhosis with ascites  
Serum creatinine > 1.5 mg/dl 
No sustained improvement of serum creatinine (a decrease in serum <1.5 mg/dl) after at least 2 days of 
diuretic withdrawal and volume expansion with albumin (recommended dose of 1g/kg of body per day 
up to a maximum dose of 100g/day)  
Absence of chock 
No current or recent treatment with nephrotoxic drugs  
Absence of signs of parenchymal disease, as indicated by proteinuria > 500mg per day, microhematuria 
(>50 red blood cells per high power field) and/or abnormal renal ultrasound   
Adapted from “Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis” [16] 
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